Red List

MLYSMineralys Therapeutics, Inc.

Healthcare · Biotechnology · mid-cap ($2.4B)
-46.0%
from rolling 252-day high of $47.65 set 2025-11-12 · 281d ago
Current
$25.75
Decline depth
-46.0%
Decline σ
5.2σ
TFC
4/5 bearish
Rolling 252-day high Up day Down day Last 90 trading days · data from Alpaca

Since tracking began

$MLYS has been tracked since 2026-03-01. It was down 38.5% from its 52-week high then — now down -46.0%.

That's 7.7 percentage points deeper than the day it joined. It bottomed 52.8% below that high along the way.

Decline from the 52-week high as it stood on 2026-03-02 (fixed anchor) → today. Split-adjusted, Alpaca. Observed history, not a forecast.

Structural break signals

MLYS qualifies for the Red List on decline depth.

Decline depth
-46.0%
From rolling 252-day high of $47.65, 281d ago. Past the 40% Red List threshold.
Time-frame continuity
4/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3. Past the 4/5 Amber threshold.
Decline sigma
5.2σ
Drop from local high over the last 20 bars, expressed in units of the stock's typical daily volatility (1.98% per day). Past the ≥4σ Watch threshold.

The structural read

What price action says about MLYS.

MLYS qualifies for the Red List on decline depth — down -46.0% from its rolling 252-day high. Past the 40% threshold, the deepest tier in the taxonomy.

Cross-confirmation: also showing 4/5 bearish time frames.

Cross-confirmation: decline sigma also reads 5.2σ over 20 bars.

Upstream TFC read: weak alignment, current phase daily. Last bar types — daily 2D (red), weekly 2D (green), monthly 2D (red).

Earnings on file: 2026-05-06. Tiering is unaffected by earnings dates — listings reflect price structure only.

Questions about MLYS

What people ask.

Why is MLYS on Broken Stocks?

MLYS qualifies for the Red List on decline depth. It is down -46.0% from its rolling 252-day high of $47.65, set on 2025-11-12 — 281d ago.

Is MLYS a falling knife?

Not by the strict technical definition. MLYS is down -46.0% from its 52-week high, but that high was set 281d ago — more than 120 days. A falling knife is usually a recent breakdown from a fresh high, not an established multi-quarter downtrend. MLYS is still on the Red List for decline depth, but the freshness component of a falling knife is missing.

Is MLYS a buy?

Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.

Where is MLYS trading inside its 52-week range?

At $25.75, MLYS sits 37.5% of the way from its 52-week low ($12.59) to its 52-week high ($47.65). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.

How fast has MLYS been declining?

The current 46.0% decline accrued over 281d, which annualizes to roughly -59.8% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.

How does MLYS compare to its sector?

There are 143 other Healthcare tickers on Broken Stocks: 69 Red, 35 Amber, 39 Watch, with 50 showing recovering structural signals. Median sector decline is -36.1% — MLYS's decline is deeper than the sector median.

Does MLYS's earnings date affect its tier?

No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-05-06) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.